CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Editas Medicine Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Editas Medicine Inc
11 Hurley St
Phone: (617) 401-9000p:617 401-9000 CAMBRIDGE, MA  02141-2110  United States Ticker: EDITEDIT

Business Summary
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board EmmaReeve 6/1/2023 9/8/2021
President, Chief Executive Officer, Director Gilmore N.O Neill 59 6/1/2022 6/1/2022
Chief Financial Officer, Executive Vice President Erick J.Lucera 56 5/17/2023 5/17/2023
10 additional Officers and Directors records available in full report.

Business Names
Business Name
EDIT
Editas Medicine, LLC
Editas Securities Corporation Delaware

General Information
Number of Employees: 265 (As of 2/1/2024)
Outstanding Shares: 81,813,850 (As of 2/23/2024)
Shareholders: 19
Stock Exchange: NASD
Federal Tax Id: 464097528
Fax Number: (302) 655-5049
Email Address: info@editasmed.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024